### 2017 WAGO ANNUAL MEETING
WESTERN ASSOCIATION OF GYNECOLOGIC ONCOLOGISTS
June 14-17, 2017 | Ritz-Carlton Rancho Mirage, Rancho Mirage, California

<table>
<thead>
<tr>
<th>DATE/TIME</th>
<th>FUNCTION</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday, June 14, 2017</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00pm - 6:00pm</td>
<td>Exhibits/Poster Set-up</td>
<td>Salon 1&amp;2</td>
</tr>
<tr>
<td>4:00pm - 7:00pm</td>
<td>Conference Registration</td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>6:30pm - 8:00pm</td>
<td>Welcome Reception</td>
<td>Ballroom Terrace</td>
</tr>
<tr>
<td><strong>Thursday, June 15, 2017</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:45am - 7:45am</td>
<td>WAGO Executive Board Meeting</td>
<td>The Boardroom</td>
</tr>
<tr>
<td>7:00am - 12:00pm</td>
<td>Conference Registration</td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Continental Breakfast</td>
<td>Salon 1&amp;2</td>
</tr>
<tr>
<td>7:00am - 12:00pm</td>
<td>Exhibit/Poster Hall</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>8:00am - 8:10am</td>
<td>Opening Remarks, Presidential &amp; Program Chair Welcome</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:10am - 10:00am</td>
<td>Scientific Session I</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:10am - 8:20am</td>
<td>Abstract 1: Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology; Lauren Prescott, MD, MPH, MD Anderson Cancer Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:20am - 8:25am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:25am - 8:35am</td>
<td>Abstract 2: The Effect of Weight Based Chemotherapy Dosing in a Cohort of Gynecologic Oncology Patients: A Follow-Up Study, Heather Williams, MD, University of Iowa Hospitals &amp; Clinics</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:35am - 8:40am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:40am - 8:50am</td>
<td>Abstract 3: Disparities in the Rates of HPV Vaccine Series Completion for Cervical Cancer Prevention, Alexandra Freeman, MD, University of Oklahoma Health Sciences Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:50am - 8:55am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:55am - 9:05am</td>
<td>Abstract 4: The use of direct oral anticoagulants for the treatment of venous thromboembolism in patients with gynecologic malignancies; Victoria Perkins, MD, University of Oklahoma Health Sciences Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:05am - 9:10am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:10am - 9:20am</td>
<td>Abstract 5: Short Term Impact of Surgically Induced Menopause on Cognitive Function and Well-Being in Women at High Risk for Ovarian Cancer following RRSO; Heidi Chang, MD, Cedars Sinai Medical Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:20am - 9:25am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:25am - 10:25am</td>
<td>ASCO Update: Kathleen Moore, MD</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:25am - 11:00am</td>
<td>Break &amp; View Posters</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>11:00am - 12:00pm</td>
<td>Scientific Session II</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:00am - 11:10am</td>
<td>Abstract 6: HPV Vaccination of Adolescent Males in the U.S.: Physician Recommendation Needs to Focus on Safety and Necessity, Not Gender and Sexuality; Anna Beavis, MD, MPH, John Hopkins Hospital</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:10am - 11:15am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:15am - 11:25am</td>
<td>Abstract 7: Pilot Evaluation of Cervical Cancer Screening Modalities in a Low Resource Ugandan Setting; Sigita Cahoon, MD, University of Southern California</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:25am - 11:30am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>Time</td>
<td>Activity</td>
<td>Location</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>11:30am - 11:40am</td>
<td>Abstract 8: Feasibility of Integrated PET/MRI and PET/CT Imaging for Gynecological Malignancies; Melissa Schwartz, MD, Icahn School of Medicine at Mount Sinai</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:40am - 11:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:45am - 11:55am</td>
<td>Abstract 9: Ethnic Disparities in Screening, Treatment and Outcomes in Women with Cervical Carcinoma; Kelly Davis, MD Tulane University School of Medicine</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:55am - 12:00pm</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>12:00pm - 1:30pm</td>
<td>Lunch &amp; Learn</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>2:30pm - 4:30pm</td>
<td>Networking Event</td>
<td>Palm Springs Aerial Tramway</td>
</tr>
<tr>
<td><strong>Friday, June 16, 2017</strong></td>
<td><strong>Function</strong></td>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>7:00am - 1:30pm</td>
<td>Conference Registration</td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Continental Breakfast</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>7:00am - 1:30pm</td>
<td>Exhibit/Poster Hall</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>8:00am - 10:00am</td>
<td>Scientific Session III</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:00am - 8:10am</td>
<td>Abstract 10: Favorable tumor immunophenotype is associated with homologous recombination deficiency in ovarian carcinoma; Christopher Morse, MD, University of Washington</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:10am - 8:15am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:15am - 8:25am</td>
<td>Abstract 11: Mechanism of tumor suppressor miRNA let-7 downregulation in ovarian cancer; transcription factor Snail represses let-7 and is associated with invasiveness phenotype; Yevgeniya Ioffe, MD, Loma Linda University School of Medicine</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:25am - 8:30am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:30am - 8:40am</td>
<td>Abstract 12: Pretty Fly for GPI: Altered Carbohydrate Metabolism in Ovarian Cancer; Rebecca Previs, MD, MD Anderson Cancer Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:40am - 8:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:45am - 8:55am</td>
<td>Abstract 13: Carboplatin synergizes with CA125-targeted TRAIL variant Meso64-TR3 via death receptor, caspase-3 and TNF-α upregulation: a novel targeted therapy for ovarian cancer.; James Cripe, MD, Washington University</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:55am - 9:00am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:00am - 9:10am</td>
<td>Abstract 14: A Cost-Effectiveness Analysis of Three PARP Inhibitors for Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer; Annie Liu, MD, UCLA/Cedars-Sinai Medical Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:10am - 9:15am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:15am - 9:25am</td>
<td>Abstract 15: BRCA1, DNA repair associated (BRCA1)- and BRCA1 Interacting Protein C-terminal Helicase 1 (BRIP1)-Mutated Ovarian Epithelial Cells Acquire a Cancer Stem Cell-Like Phenotype and Decreased Sensitivity to Cisplatin and Olaparib in Three Dimensional Spheroid Culture; Crystal Adams, MD, University of Southern California</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:25am - 9:30am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:30am - 9:40am</td>
<td>Abstract 16: Shifts in Practice Patterns: Addressing Disparities in Ovarian Cancer Care; Priyanka Kamath, MD, University of Miami</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:40am - 9:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:45am - 9:55am</td>
<td>Abstract 17: Prodrug Activator Gene Therapy of Ovarian Cancer using a Retroviral Replicating Vector; Sara Collins, PhD, University of Miami</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:55am - 10:00am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:00am - 10:30am</td>
<td>Break &amp; View Posters</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>10:30am - 11:45pm</td>
<td>Scientific Session IV</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Location</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>10:30am - 10:40am</td>
<td>Abstract 18: Tolerance and Toxicity of the PARP Inhibitor Olaparib in Older Women with Ovarian Cancer; Lauren Dockery, MD, University of Oklahoma Health Sciences Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:40am - 10:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:45am - 10:55am</td>
<td>Abstract 19: A Genomic Rearrangement Signature Associated with Poor Overall Survival in High Grade Serous Ovarian Cancer; Robert Hillman, MD, PhD, The University of Texas M.D. Anderson Cancer Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:55am - 11:00am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:00am - 11:10am</td>
<td>Abstract 20: Imaging Biomarkers of Adiposity and Sarcopenia as Potential Predictors for Overall Survival Among Patients with Endometrial Cancer Treated with Bevacizumab; Jessica Gillen, MD, The University of Oklahoma Health Science Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:10am - 11:15am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:15am - 11:25am</td>
<td>Abstract 21: Germline BRCA mutation rate in Southern California Latina women; Linda Hong, MD, Loma Linda University Medical Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:25am - 11:30am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:30am - 11:40am</td>
<td>Abstract 22: Co-expression of the Hypoxic Marker Carbonic Anhydrase 9 (CA-IX) with Breast Cancer Associated 1 (BRCA1) is associated with faster recurrence in High Grade Serous Adenocarcinoma.; Adam Krieg, PhD, Oregon Health &amp; Science University</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:40am - 11:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:45am - 11:55am</td>
<td>Abstract 23: Inhibition of the Receptor Tyrosine Kinase AXL Sensitizes Uterine Serous Cancer to Paclitaxel via Increased Accumulation of Paclitaxel in Tumor Cells; Jeanne Quinn, BS, Washington University School of Medicine</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:55am - 12:05pm</td>
<td>Case 1: by Henry Reyes, MD</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>12:05pm - 12:11pm</td>
<td>Case 2: by Varvara Mazina, MD</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>12:11pm - 12:25pm</td>
<td>Case 3: by Danielle Chau, MD</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>12:25pm - 12:45pm</td>
<td>Case 4: by Sarah E. Paraghamian, MD</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>12:45pm - 1:30pm</td>
<td>Presidential Lectureship: Ovarian Cancer: State of the Science; Michael Birrer, MD, PhD</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>6:30pm - 8:00pm</td>
<td>WAGO President's Reception</td>
<td>Vista Lawn</td>
</tr>
</tbody>
</table>

**Saturday, June 17, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 12:00pm</td>
<td>Conference Registration</td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Continental Breakfast</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>7:00am - 12:00pm</td>
<td>Exhibit/Poster Hall</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>8:00am - 10:00am</td>
<td>Scientific Session V</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:00am - 8:10am</td>
<td>Abstract 23: Inhibition of the Receptor Tyrosine Kinase AXL Sensitizes Uterine Serous Cancer to Paclitaxel via Increased Accumulation of Paclitaxel in Tumor Cells; Jeanne Quinn, BS, Washington University School of Medicine</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:10am - 8:15am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:15am - 8:25am</td>
<td>Abstract 24: Identification of Clinical-Molecular Characteristics Associated with Recurrent Endometrial Cancer; Andreea Newston, MD, University of Iowa Hospitals and Clinics</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:25am - 8:30am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:30am - 8:40am</td>
<td>Abstract 25: Treatment with SQ1274, a Novel Tubulin Polymerization Inhibitor, Results in Improved Therapeutic Efficacy Compared to Paclitaxel in Serous Gynecologic Cancers; Kathryn Mills, MD, Washington University School of Medicine</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>8:40am - 8:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:45am - 8:55am</td>
<td>Abstract 26: Clinical and Genomic Differences by Loss of Heterozygosity Status in Recurrent Ovarian Cancer; Laura Holman, MD, The University of Oklahoma Health Sciences Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>8:55am - 9:00am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:00am - 9:10am</td>
<td>Abstract 27: High Rates of Minimally Invasive Hysterectomy Surgery for Endometrial Cancer at National Comprehensive Cancer Network Centers; Jennifer Bergstrom, MD, Johns Hopkins Hospital</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:10am - 9:15am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:15am - 9:25am</td>
<td>Abstract 28: Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I endometrioid endometrial cancer; Koji Matsuo, MD, PhD, University of Southern California</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:25am - 9:30am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:30am - 9:40am</td>
<td>Abstract 29: Patient Satisfaction After Open Gynecologic Oncology Surgery With Enhanced Recovery Pathway; Natsai Nyakudarika, MD, University of California, San Francisco</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:40am - 9:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:45am - 9:55am</td>
<td>Abstract 30: A cost-effectiveness analysis of universal testing for Lynch syndrome in endometrial carcinoma; Joseph Dottino, MD, MPH, MD Anderson Cancer Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>9:55am - 10:00am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:00am - 10:30am</td>
<td>Break &amp; View Posters</td>
<td>Salon 1 &amp; 2</td>
</tr>
<tr>
<td>10:30am - 12:00pm</td>
<td>Scientific Session VI</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:30am - 10:40am</td>
<td>Abstract 31: Younger Age as a Strong Predictor of Increased Total Narcotic Usage While Undergoing Robotic Assisted Laparoscopy Surgery; Andrea Morena, MD, Phoenix Integrated Residency in Obstetrics and Gynecology</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:40am - 10:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:45am - 10:55am</td>
<td>Abstract 32: Survival across lines of therapy in uterine leiomyosarcoma; Victoria Perkins, MD, University of Oklahoma Health Sciences Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>10:55am - 11:00am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:00am - 11:10am</td>
<td>Abstract 33: Discrepancies in outside pathology slide review of uterine neoplasms; Carolyn Haunschild, MD, Stanford Hospital</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:10am - 11:15am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:15am - 11:25am</td>
<td>Abstract 34: Robotic-assisted Gynecologic Surgery in an Elderly Population: A Comparison Study; Elise Vo, MD, St. Joseph Hospital and Medical Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:25am - 11:30am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:30am - 11:40am</td>
<td>Abstract 35: Adjuvant Therapy for Grade 3, Deeply Invasive Endometrioid Adenocarcinoma of the Uterus; Michaela Onstad, MD, MPH, MD Anderson Cancer Center</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:40am - 11:45am</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:45am - 11:55am</td>
<td>Abstract 36: Effect of Diabetes and Metformin on Uterine Risk Factors in Type 2 Endometrial Cancers; Iman Alsaden, MD, University of Chicago</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>11:55am - 12:00pm</td>
<td>Question &amp; Answer</td>
<td>Salon 3 &amp; 4</td>
</tr>
<tr>
<td>12:00pm</td>
<td>Conference Adjourns</td>
<td>Salon 3 &amp; 4</td>
</tr>
</tbody>
</table>